Bill Text: NY S05935 | 2019-2020 | General Assembly | Amended
Bill Title: Relates to medication assisted treatment for substance abuse disorders; prohibits prior authorization.
Spectrum: Partisan Bill (Democrat 5-0)
Status: (Vetoed) 2020-01-01 - VETOED MEMO.292 [S05935 Detail]
Download: New_York-2019-S05935-Amended.html
STATE OF NEW YORK ________________________________________________________________________ 5935--A Cal. No. 1170 2019-2020 Regular Sessions IN SENATE May 16, 2019 ___________ Introduced by Sens. HARCKHAM, BIAGGI, CARLUCCI, KAPLAN -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- committee discharged and said bill committed to the Commit- tee on Rules -- reported favorably from said committee, ordered to a third reading, passed by Senate and delivered to the Assembly, recalled, vote reconsidered, restored to third reading, amended and ordered reprinted, retaining its place in the order of third reading AN ACT to amend the social services law and the public health law, in relation to medication for the treatment of substance use disorders The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. Subdivision 2 of section 365-a of the social services law 2 is amended by adding a new paragraph (gg) to read as follows: 3 (gg) all buprenorphine products, methadone or long acting injectable 4 naltrexone for detoxification or maintenance treatment of a substance 5 use disorder prescribed according to generally accepted national profes- 6 sional guidelines for the treatment of a substance use disorder. Such 7 medication assisted treatment shall not be subject to any prior authori- 8 zation mandate. 9 § 2. Subdivision 26-b of section 364-j of the social services law, as 10 added by section 4 of part B of chapter 69 of the laws of 2016, is 11 amended to read as follows: 12 26-b. Managed care providers shall not require prior authorization for 13 [an initial or renewal prescription for buprenorphine or injectable14naltrexone for detoxification or maintenance treatment of opioid15addiction unless the prescription is for a non-preferred or non-formu-16lary form of the drug or as otherwise required by section 1927(k)(6) of17the Social Security Act] any buprenorphine products, methadone or long 18 acting injectable naltrexone for detoxification or maintenance treatment 19 of a substance use disorder prescribed according to generally accepted EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD10713-06-9S. 5935--A 2 1 national professional guidelines for the treatment of a substance use 2 disorder. 3 § 3. Subdivision 10 of section 273 of the public health law, as added 4 by section 5 of part B of chapter 69 of the laws of 2016, is amended to 5 read as follows: 6 10. Prior authorization shall not be required for [an initial or7renewal prescription for buprenorphine or injectable naltrexone for8detoxification or maintenance treatment of opioid addiction unless the9prescription is for a non-preferred or non-formulary form of such drug10as otherwise required by section 1927(k)(6) of the Social Security Act] 11 any buprenorphine products, methadone or long acting injectable naltrex- 12 one for detoxification or maintenance treatment of a substance use 13 disorder prescribed according to generally accepted national profes- 14 sional guidelines for the treatment of a substance use disorder. 15 § 4. This act shall take effect on the ninetieth day after it shall 16 have become a law; provided, however, that the amendments to subdivision 17 26-b of section 364-j of the social services law made by section two of 18 this act shall not affect the repeal of such section, and shall be 19 deemed repealed therewith.